Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Letter to the Editor
  • Published:

hOCT1 transcript levels and single nucleotide polymorphisms as predictive factors for response to imatinib in chronic myeloid leukemia

Leukemia volume 24, pages 1243–1245 (2010)Cite this article

Subjects

The probability of achieving an optimal response to treatment in CML is most likely to be influenced by the variable capacity of a given patient's leukemia cells to accumulate intracellular imatinib (IM). The transport of IM into the cells is an active process mediated by the human organic cation transporter (hOCT1) protein, a membrane associated ATP-dependent protein channel.1 Recently we reported that higher levels of hOCT1 transcript levels in blood derived white cells (WBC) collected at diagnosis predicted for a 3-log reduction in BCR-ABL1 transcript levels (major molecular response, MMR) and also for greater degrees of transcript reduction in patients who had achieved complete cytogenetic responses (CCyR).2 Investigators in Liverpool also showed that higher hOCT1 transcript levels in diagnostic WBC predicted for a better response to IM.3 The mean hOCT1 mRNA level in pre-IM bone marrow mononuclear cells (MNC) was also reported to be lower in the patients who failed to achieve CCyR by 12 months of therapy.4 However a recent study of total WBC collected from newly diagnosed patients before starting IM failed to confirm any correlation between hOCT1 transcript levels and response to IM.5 These conflicting reports on the predictive value of hOCT1 transcript levels2, 3, 4, 5 might be due to the different target cells studied, to different primers and probes used to measure hOCT1 mRNA or to differing phases of the disease when the hOCT1 was measured.

We also measured hOCT1 in WBC from paired samples collected at diagnosis and at attainment of complete cytogenetic response (CCyR) in 60 patients treated with IM. The hOCT1 transcript level was significantly higher (P<0.0001) in samples collected in CCyR (range: 0.15–8.88, median: 2.2) compared to the matching diagnostic samples (range: 0.02–3.511, median: 0.14) (Figure 1b). The obvious difference at these two time points is that cells collected from blood at the time of CCyR are derived from normal rather than leukemic haemopoiesis. The relative increase in the hOCT1 transcript level in the CCyR samples could be due to an inhibitory effect of the BCR-ABL1 oncoprotein on the expression of hOCT1 in leukemic cells. As shown in Figure 1c, the level of hOCT1 transcripts in total WBC in CCyR samples (n=60) from patients on IM was not significantly different (P=0.156) from the level of hOCT1 in total WBC from normal individuals (n=21), which supports this explanation. This hypothesis is indirectly supported by the observation of a reduction in hOCT1 transcript levels in CML blast crisis samples5 which in turns is associated with increased level of BCR-ABL1 transcripts.6

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

References

  1. Thomas J, Wang L, Clark RE, Pirmohamed M . Active transport of imatinib into and out of cells: implications for drug resistance. Blood 2004; 104: 3739–3745.

    Article  CAS  PubMed  Google Scholar 

  2. Marin D, Bazeos A, Mahon F-X, Eliason L, Milojkovic D, Bua M et al. Adherence is the critical factor for achieving molecular responses in chronic myeloid leukemia patients who achieve complete cytogenetic responses on imatinib. J Clin Oncol; e-pub ahead of print 12 April 2010.

  3. Wang L, Giannoudis A, Lane S, Williamson P, Pirmohamed M, Clark RE . Expression of the uptake drug transporter hOCT1 is an important clinical determinant of the response to imatinib in chronic myeloid leukemia. Clin Pharmacol Ther 2008; 83: 258–264.

    Article  CAS  PubMed  Google Scholar 

  4. Crossman LC, Druker BJ, Deininger MW, Pirmohamed M, Wang L, Clark RE . hOCT 1 and resistance to imatinib. Blood 2005; 106: 1133–1134.

    Article  CAS  PubMed  Google Scholar 

  5. Zhang WW, Cortes JE, Yao H, Zhang L, Reddy NG, Jabbour E et al. Predictors of primary imatinib resistance in chronic myelogenous leukemia are distinct from those in secondary imatinib resistance. J Clin Oncol 2009; 27: 3642–3649.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Gaiger A, Henn T, Horth E, Geissler K, Mitterbauer G, Maier-Dobersberger T et al. Increase of bcr-abl chimeric mRNA expression in tumor cells of patients with chronic myeloid leukemia precedes disease progression. Blood 1995; 86: 2371–2378.

    CAS  PubMed  Google Scholar 

  7. Kim DH, Xu W, Ma C, Liu X, Siminovitch K, Messner HA et al. Genetic variants in the candidate genes of the apoptosis pathway and susceptibility to chronic myeloid leukemia. Blood 2009; 113: 2517–2525.

    Article  CAS  PubMed  Google Scholar 

  8. Shu Y, Brown C, Castro RA, Shi RJ, Lin ET, Owen RP et al. Effect of genetic variation in the organic cation transporter 1, OCT1, on metformin pharmacokinetics. Clin Pharmacol Ther 2008; 83: 273–280.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Haematology, Imperial College London, Hammersmith Hospital, London, UK

    A Bazeos, D Marin, A G Reid, G Gerrard, D Milojkovic, P C May, H de Lavallade, P Garland, K Rezvani, J F Apperley, J M Goldman, L Foroni & J S Khorashad

Authors
  1. A Bazeos
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. D Marin
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A G Reid
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. G Gerrard
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. D Milojkovic
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. P C May
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. H de Lavallade
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. P Garland
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. K Rezvani
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. J F Apperley
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. J M Goldman
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. L Foroni
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. J S Khorashad
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to J S Khorashad.

Ethics declarations

Competing interests

D Marin, JF Apperley, JM Goldman, D Milojkovic and K Rezvani receive honoraria and/or research funds from Novartis Pharmaceuticals. However, Novartis had no role in the design of the study, collection of the data or the decision to publish.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bazeos, A., Marin, D., Reid, A. et al. hOCT1 transcript levels and single nucleotide polymorphisms as predictive factors for response to imatinib in chronic myeloid leukemia. Leukemia 24, 1243–1245 (2010). https://doi.org/10.1038/leu.2010.86

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/leu.2010.86

This article is cited by

Search

Advanced search

Quick links